OR WAIT null SECS
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Chronic Obstructive Pulmonary Disease (COPD).
This is Clinilabs’ third clinical trial examining drug effects in patients with COPD. “As a specialty CRO, it is exciting to grow our franchise in respiratory disorders as we expand our expertise to an ever wider range of conditions” states Barbara Smallwood, Vice President of Business Development at Clinilabs.
Enrollment for this study is expected to begin in April 2011.